186.66
2.26%
4.175
Charles River Laboratories International Inc stock is traded at $186.66, with a volume of 404.22K.
It is up +2.26% in the last 24 hours and down -2.17% over the past month.
See More
Previous Close:
$182.48
Open:
$180.89
24h Volume:
404.22K
Relative Volume:
0.56
Market Cap:
$10.63B
Revenue:
$4.08B
Net Income/Loss:
$431.79M
P/E Ratio:
19.79
EPS:
9.43
Net Cash Flow:
$486.92M
1W Performance:
+1.41%
1M Performance:
-2.17%
6M Performance:
-20.08%
1Y Performance:
+2.58%
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
Sep-13-23 | Initiated | TD Cowen | Market Perform |
Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
May-24-22 | Initiated | Guggenheim | Neutral |
Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
Apr-07-22 | Initiated | Stephens | Overweight |
Feb-17-22 | Reiterated | BofA Securities | Buy |
Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
Feb-17-22 | Reiterated | Deutsche Bank | Buy |
Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
Feb-17-22 | Reiterated | UBS | Buy |
Aug-05-21 | Resumed | Credit Suisse | Neutral |
Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
May-13-20 | Upgrade | UBS | Neutral → Buy |
Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-02-20 | Initiated | Deutsche Bank | Buy |
Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
Jan-08-20 | Initiated | Wells Fargo | Overweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Jun-10-19 | Initiated | SVB Leerink | Outperform |
Apr-30-19 | Resumed | Evercore ISI | Outperform |
Dec-14-18 | Initiated | Deutsche Bank | Buy |
Oct-09-18 | Initiated | UBS | Neutral |
Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Laboratories Q3 2024 Earnings Preview - MSN
Stephens Inc. AR Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Cell Banking Outsourcing Market Report: Detailed Insights - openPR
Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance
abrdn plc Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Gmp Cell Banking Services Market Size, Share, and Forecast - openPR
Restructuring update likely in Charles River Labs’ Q3 earnings - The Business Journals
Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update - MarketBeat
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Zacks Research Has Weak Forecast for CRL FY2024 Earnings - MarketBeat
Congress Asset Management Co. Sells 9,239 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
WD Rutherford LLC Has $338,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International (CRL) to Release Earnings on Wednesday - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
Fragment Based Drug Discovery Market Size Projected to Achieve USD 2.1 Billion by 2031, Expanding at a 11.5% CAGR | Analysis by Transparency Market Research, Inc. - GlobeNewswire Inc.
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research
The Latest Breaking News from Charles River Laboratories - Inkl
Charles River Laboratories' Q3 2024 Earnings: What to Expect - TradingView
Charles River Laboratories' Q3 2024 Earnings: What To Expect - Barchart
Assenagon Asset Management S.A. Acquires 29,621 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Ophthalmic Clinical Trials Market Intelligence Reports - openPR
Boston Trust Walden Corp Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet - Simply Wall St
Dumont & Blake Investment Advisors LLC Sells 4,360 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
CLSA Begins Coverage on Charles River Laboratories International (NYSE:CRL) - MarketBeat
Charles River Laboratories International (NYSE:CRL) Trading Down 4.9%Should You Sell? - MarketBeat
Charles River Laboratories International Inc (CRL) Shares Down 3 - GuruFocus.com
CRL Gears Up for Q3 Earnings: Here's What You Need to Know - Yahoo Finance
Charles River Launches Retrogenix Non-Human Protein Library - Contract Pharma
FibroBiologics and Charles River link for chronic disease therapies manufacture - Yahoo News
Allspring Global Investments Holdings LLC Acquires 509,163 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch - Yahoo Finance
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - Yahoo Finance
Research Analysts Set Expectations for CRL Q3 Earnings - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Stock Position Decreased by SG Americas Securities LLC - MarketBeat
Genetic Toxicology Testing Market to See Booming Growth - openPR
Charles River Launches New Retrogenix® Non-Human Protein Library - sharewise
December 20th Options Now Available For Charles River Laboratories International (CRL) - Nasdaq
Charles River Launches Non-Human Protein Library - Baystreet.ca
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call - sharewise
CRLCharles River Laboratories International, Inc. Latest Stock News & Market Updates - StockTitan
meQuilibrium Honors JPMorganChase, Dow Chemical, Liberty Mutual Insurance, Leidos, KBR, Charles River Labs, Point32 Health, and Qurate Retail Group for Achievements in Supporting Employee Resilience - PR Newswire
Charles River Laboratories International (NYSE:CRL) Upgraded to Buy by StockNews.com - MarketBeat
Cellular and Gene Therapy CDMO Market Year 2034|Catalent, Lonza, Charles River, The Discovery Labs, BIOCENTRIQ, FUJIFILM – IndiaPolitics.com - IndiaPolitics.com
Cell Banking System Market Demand With Future Forecast – WuXi AppTec, Charles River Laboratories International, Eurofins Scientific, Merck KGaA – Cauverynews - Cauverynews
Charles River Labs stock under pressure amid COVID backlog normalization By Investing.com - Investing.com South Africa
Charles River Labs stock under pressure amid COVID backlog normalization - Investing.com India
Charles River Laboratories International (NYSE:CRL) Receives New Coverage from Analysts at Redburn Atlantic - MarketBeat
Clinical Trials Market 2024-2031: Global Industry Size, Share, - openPR
Cell Banking Outsourcing Market Size, Share, and Forecast - openPR
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):